Moxetumomab Pasudotox

Category: Cancer



Moxetumomab Pasudotox Overview

Moxetumomab pasudotox, sold under the brand name Lumoxiti, is an anti-CD22 immunotoxin for the treatment of adults with relapsed or refractory hairy cell leukemia (HCL) who have received at least two prior systemic therapies, including treatment with a purine nucleoside analog.[2] Moxetumomab pasudotox is a CD22-directed cytotoxin and is the first of this type of treatment for adults with HCL.[2] The drug consists of the binding fragment (Fv) of an anti-CD22 an...

Read more Moxetumomab Pasudotox Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Moxetumomab_pasudotox

Recent Moxetumomab Pasudotox Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Moxetumomab Pasudotox
  • Injection: 1mg/vial
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

Other drugs which contain Moxetumomab Pasudotox or a similar ingredient: (1 result)




Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. This page was last updated on 24 September 2020.

We are committed to your privacy.

Copyright © 2005-2020 All Rights Reserved. MedsChat® is a registered trademark of Limelight Innovations L.L.C. 9888 W Belleview Ave #5000, Denver, CO, 80123, USA